58 results match your criteria: "Jefferson Cancer Center[Affiliation]"
J Geriatr Oncol
May 2020
Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States of America.
Background: While a number of landmark clinical trials have led to the approval of combination chemotherapy regimens for metastatic pancreatic adenocarcinoma (mPC), older patients are underrepresented in these studies. We evaluated changes in practice patterns in the management of mPC among medical oncologists in the combination chemotherapy era (CCE).
Methods: A retrospective analysis of patients treated at a tertiary cancer center between 2000 and 2015 was conducted.
Ann N Y Acad Sci
October 1996
Thomas Jefferson University, Jefferson Cancer Center, Department of Microbiology and Immunology, Philadelphia, Pennsylvania 19107-6799, USA.
Protein Eng
August 1996
Department of Pharmacology, Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Molecular models of HIV-1 protease and 21 peptide substrates with single amino acid substitutions at positions from P4 to P3' were built and compared with kinetic measurements. The crystal structure of HIV-1 protease with a peptidic inhibitor was modified to model the peptide substrate Pro-Ala-Val-Ser-Leu-Ala-Met-Thr for the starting geometry. Models were built of two reaction intermediates, HIV protease with peptide substrate and with its tetrahedral intermediate.
View Article and Find Full Text PDFUrology
June 1996
Department of Urology, Thomas Jefferson University and the Jefferson Cancer Center, Philadelphia, Pennsylvania 19107-5097, USA.
Objectives: There is interest in treating prostate cancer with induction androgen deprivation prior to radical prostatectomy. Data on long-term prostate-specific antigen (PSA)-based survival analyses among patients treated with neoadjuvant hormonal therapy (NHT) and prostatectomy are limited. In 1991 we instituted a pilot study for T3 disease based on endorectal coil magnetic resonance imaging (eMRI), mandatory negative laparoscopic nodal dissection prior to hormonal manipulation, and prostatectomy followed by pathologic and PSA-based outcome determinations.
View Article and Find Full Text PDFUrology
June 1996
Department of Urology, Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Objectives: Different molecular forms of prostate-specific antigen (PSA) appear to be expressed by benign prostatic hyperplasia (BPH) compared with prostate cancer. These differences are not well understood and may arise from aberrant RNA splicing, altered protein glycosylation, or variant PSA complexing to macroglobulins. To our knowledge, a direct comparison of PSA mRNA sequences in BPH versus prostate cancer to account for these differences has not been reported.
View Article and Find Full Text PDFTech Urol
April 1997
Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Recent reports have suggested the shedding of cancer cells during radical extirpation of tumors. Prostate cells can be expressed from the prostate ex vivo and found in the expressed prostatic secretions. We conducted an in vivo study to determine if prostate epithelial cells can be found in the operative site as determined by RT-PCR targeted at prostate specific antigen (PSA) and to correlate this with pathologic stage and outcome.
View Article and Find Full Text PDFGenome Res
April 1996
Department of Microbiology and Immunology, Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107-5541, USA.
Mice carrying the Tight skin (Tsk) mutation have thickened skin and visceral fibrosis resulting from an accumulation of extracellular matrix molecules. These and other connective tissue abnormalities have made Tskl + mice models for scleroderma, hereditary emphysema, and myocardial hypertrophy. Previously we localized Tsk to mouse chromosome 2 in a region syntenic with human chromosome 15.
View Article and Find Full Text PDFOncogene
March 1996
Jefferson Cancer Center, Thomas Jefferson University, Philadelphia. Pennsylvania 19107, USA.
THe type 1 insulin-like growth factor receptor (IGF-IR) plays an important role in mitogenesis and transformation. It has been previously shown that mitogenic signaling and transforming activity of the IGF-IR can be dissociated: a receptor truncated at residue 1229 (C-terminus) is fully mitogenic, in terms of its response to IGF-I, but cannot transform 3T3-like cells that are devoid of endogenous IGF-IRs (R- cells). We have extended our mutational analysis of the C-terminus of the human IGF-IR, by stably transfecting several mutant receptors into R- cells, and testing the resulting cell lines for IGF-I-mediated mitogenic response and formation of colonies in soft agar.
View Article and Find Full Text PDFMol Gen Genet
March 1996
Department of Pharmacology, Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
The RecA protein of Escherichia coli catalyzes homologous pairing and strand exchange between a wide range of molecules showing nucleotide sequence complementarity, including a linear duplex and a single-stranded DNA molecule. We demonstrate that RecA can promote formation of joint molecules when the duplex contains an RNA/DNA hairpin and a single-stranded circle serves as the pairing partner. A chimeric RNA/DNA hairpin can be used to form stable joint molecules with as little as 15 bases of shared homology as long as the RNA stretch contains complementarity to the circle.
View Article and Find Full Text PDFInt J Cancer
March 1996
Jefferson Cancer Center, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA.
The cyclin-dependent kinase-4 inhibitor gene CDKN2, localized at chromosome region 9p21, has been shown to be a familial melanoma gene, though we found that mutations of it are rare in uncultured sporadic melanomas. To determine Whether the region of allelic loss at 9p21 frequently observed in sporadic melanomas includes the CDKN2 locus, new polymorphic microsatellite probes were isolated from the genomic segments surrounding the CDKN2 gene and used for the study of loss of heterozygosity (LOH) in melanoma. The LOH study of matched uncultured tumor-constitutional DNA pairs from 66 metastatic cutaneous and 19 primary uveal melanomas showed that 63% and 32% of the respective tumors suffered allelic loss in the 9p21 region.
View Article and Find Full Text PDFExp Cell Res
March 1996
Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Growth factor receptors may be transactivated not only by homologous receptors, but also by heterologous receptors. We have investigated this possibility, using for this purpose R-/EGFR cells, which are mouse embryo cells devoid of IGF-I receptors, but overexpressing the EGF receptor. At variance with mouse embryo cells with a wild-type number of IGF-I receptors and overexpressing the EGF receptor, R-/EGFR cells cannot grow in EGF only, nor can they form colonies in soft agar.
View Article and Find Full Text PDFCancer Res
February 1996
Jefferson Cancer Center, Jefferson Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Very little is known about the molecular and genetic mechanisms involved in prostate cancer. Previous studies have shown frequent loss of heterozygosity (40%) at chromosomal regions 8p, 10q, and 16q, suggesting the presence of tumor suppressor genes in these regions. The LNCaP cell line, established from a metastatic lesion of human prostatic adenocarcinoma, carries a t(6;16)(p21;q22) translocation.
View Article and Find Full Text PDFSemin Oncol
February 1996
Jefferson Cancer Center, Jefferson Medical College, Philadelphia, Pennsylvania, USA.
The genetic changes found in human neoplasms suggest that hematopoietic tumors develop mainly from inappropriate expression (usually overexpression) of a growth promoting gene (oncogene). In contrast, the progression to malignancy of carcinomas occurs mainly through loss of tumor suppressor genes. Gene therapy might be used to turn off an activated oncogene, eg, by antisense treatment, whereas gene therapy to overcome tumor suppressor gene loss necessarily would focus on gene replacement in the tumor cell or pharmacologically substituting for lost gene function.
View Article and Find Full Text PDFSemin Oncol
February 1996
Department of Pharmacology, Jefferson Cancer Center, Thomas Jefferson University, philadelphia, PA, USA.
A number of cellular transformations are due, in large part, to a single base mutation that alters the function of the expressed protein. Similarly, alterations in the DNA sequence of a gene involved in cell proliferation can have a significant effect on the viability of particular cells, Thus, the capacity to modulate the base sequence of such a gene would be a useful tool for cancer therapeutics. We have developed an experimental strategy that centers around site-specific DNA base mutation or correction using a unique chimeric oligonucleotide.
View Article and Find Full Text PDFOncogene
January 1996
Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
An overexpressed insulin-like growth factor I receptor (IGF-IR) allows cells to grow in IGF-I only and to form colonies in soft agar. Conversely, cells with a targeted disruption of the IGF-IR genes, R- cells, are refractory to transformation by several oncoproteins and growth factor receptors, that readily transform their wild type counterparts, W cells. Grb2 is an SH2-SH3 domains protein that links tyrosine kinase receptors to ras signalling.
View Article and Find Full Text PDFMamm Genome
September 1996
Jefferson Cancer Center, Jefferson Medical College, Department of Microbiology and Immunology, Philadelphia, Pennsylvania 19107-5541, USA.
Exp Gerontol
September 1996
Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
The expression of insulin-like growth factor I (IGF-I) is regulated by hormones, oncogenes, and other growth factors, and is markedly decreased or even absent in senescent human diploid fibroblasts. In previous articles, we have reported that the SV40 large T antigen increases the production of IGF-I and that the expression of the IGF-I gene is negatively regulated by an E2F binding site in the IGF-I promoter. We have now investigated the activity of the IGF-I promoter, in response to stimulation of cells by either PDGF or EGF.
View Article and Find Full Text PDFCell Prolif
December 1995
Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
We have transfected a plasmid expressing the transcriptional regulator GC Factor (GCF) into cell lines and have found that the GCF: 1 causes a decrease in the levels of insulin-like growth factor I receptor (IGF-IR) mRNA; 2 causes a decrease in the number of IGF-IRs; and 3 represses the activity of the IGF-IR promoter. In addition, we show that the regulation of IGF-IR expression by GCF plays a physiological role in the control of cellular proliferation in vitro.
View Article and Find Full Text PDFMol Cell Biol
October 1995
Jefferson Cancer Center, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA.
Leukemia results from the accumulation of multiple genetic alterations that disrupt the control mechanisms of normal growth and differentiation. The use of inbred mouse strains that develop leukemia has greatly facilitated the identification of genes that contribute to the neoplastic transformation of hematopoietic cells. BXH-2 mice develop myeloid leukemia as a result of the expression of an ecotropic murine leukemia virus that acts as an insertional mutagen to alter the expression of cellular proto-oncogenes.
View Article and Find Full Text PDFAnn N Y Acad Sci
September 1995
Section of Behavioral Epidemiology, Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
J Biol Chem
September 1995
Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
The wild type insulin-like growth factor I (IGF-I) receptor has both mitogenic and transforming activities. We have examined the effect of point mutations at tyrosine residues 1250 and 1251 on these two properties of the receptor. For this purpose, we stably transfected plasmids expressing mutant and wild type receptors into R- cells, which are 3T3-like cells, derived from mouse embryos with a targeted disruption of the IGF-I receptor genes, and therefore devoid of endogenous IGF-I receptors.
View Article and Find Full Text PDFBiochem Biophys Res Commun
September 1995
Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
The insulin-like growth factor I receptor (IGF-IR) plays a crucial role in cell growth, transformation and protection from apoptosis. We have transfected several mutant IGF-IRs into C6 rat glioblastoma cells, in order to determine whether they can act as dominant negatives. We find that some of them can act as dominant negatives in growth assays (monolayer or soft agar), but that none of those examined can induce apoptosis in C6 cells.
View Article and Find Full Text PDFCancer Res
September 1995
Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
We have investigated whether there is a quantitative relationship between the insulin-like growth factor I receptor (IGF-IR), the extent of apoptosis in vivo, and tumorigenesis. C6 rat glioblastoma cells were treated with increasing concentrations of antisense oligodeoxynucleotides to the IGF-IR RNA. The extent of apoptosis in vivo is correlated to the decrease in IGF-IR levels and, in turn, tumorigenesis in nude mice is correlated to the fraction of surviving cells.
View Article and Find Full Text PDFJ Virol
September 1995
Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Mouse embryo cells with a targeted disruption of the insulin-like growth factor I receptor (IGF-IR) genes (R- cells) are refractory to transformation by the simian virus 40 large T antigen and/or an activated and overexpressed Ras, both of which readily transform cells from wild-type littermate embryos and other 3T3-like cells. R- cells are also refractory to transformation induced by overexpressed epidermal growth factor receptor and platelet-derived growth factor receptor beta. Since the platelet-derived growth factor receptor beta is required for transformation by bovine papillomavirus, we inquired whether the IGF-IR was also required for transformation by bovine papillomavirus E5 oncoprotein.
View Article and Find Full Text PDFMol Cell Biol
August 1995
Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Mouse embryo cells expressing a wild-type number of insulin-like growth factor I receptors (IGF-IR) (W cells) can be transformed either by simian virus 40 large T antigen (SV40 T) or by overexpressed insulin receptor substrate 1 (IRS-1), singly transfected. Neither SV40 T antigen nor IRS-1, individually, can transform mouse embryo cells with a targeted disruption of the IGF-IR genes (R- cells). However, cotransfection of SV40 T antigen and IRS-1 does transform R- cells.
View Article and Find Full Text PDF